BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 236 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $37,217,213 | -20.6% | 5,286,536 | -5.9% | 0.04% | -25.4% |
| Q1 2023 | $46,857,222 | +77125.3% | 5,618,372 | +6.3% | 0.06% | -33.0% |
| Q4 2022 | $60,676 | -99.9% | 5,285,348 | +9.8% | 0.09% | -2.2% |
| Q3 2022 | $60,653,000 | -5.2% | 4,813,772 | -20.4% | 0.09% | +1.1% |
| Q2 2022 | $63,977,000 | -23.0% | 6,046,961 | +18.4% | 0.09% | -5.3% |
| Q1 2022 | $83,038,000 | +18.6% | 5,106,903 | +1.0% | 0.09% | +34.3% |
| Q4 2021 | $70,015,000 | +40606.4% | 5,055,264 | +42150.4% | 0.07% | – |
| Q3 2021 | $172,000 | – | 11,965 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $40,692,000 | 16.07% |
| Fairmount Funds Management LLC | 3,343,107 | $35,370,000 | 8.10% |
| Kynam Capital Management, LP | 936,563 | $9,909,000 | 2.53% |
| Velan Capital Investment Management LP | 225,000 | $2,381,000 | 2.42% |
| ORACLE INVESTMENT MANAGEMENT INC | 603,994 | $6,390,000 | 1.94% |
| TANG CAPITAL MANAGEMENT LLC | 1,200,000 | $12,696,000 | 1.93% |
| MPM BioImpact LLC | 639,089 | $6,762,000 | 1.88% |
| Ghost Tree Capital, LLC | 325,000 | $3,439,000 | 1.79% |
| Sarissa Capital Management LP | 1,390,790 | $14,715,000 | 1.48% |
| Prosight Management, LP | 176,680 | $1,869,000 | 1.47% |